RxDoctor Payments DataLook up a doctor →

Sahil Parikh, MD

Interventional Cardiology · New York, NYNPI 1023094117

Payments from drug & device makers

$2,685,309in general payments, 2019–2025

Across 955 payments — averaging $2811.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Shockwave Medical, Inc$1.6M
  • Boston Scientific$414K
  • Abbott$170K
  • Trireme Medical LLC$152K
  • Surmodics, Inc.$147K
  • Medtronic$52K
  • plus $128K from 54 others

What the payments were for

  • Consulting fees$260,17716%
  • Speaking & faculty fees$1,104,44667%
  • Grants$202,50012%
  • Travel & lodging$45,2563%
  • Food & beverage$29,2022%
  • Education$1910%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Shockwave Medical, Inc152$1,621,301
Boston Scientific199$414,413
Abbott136$169,691
Trireme Medical LLC9$152,077
Surmodics, Inc.60$147,432
Medtronic(2 entities)108$51,899
Penumbra, Inc.22$41,393
Philips North America LLC21$18,658
Cagent Vascular Inc4$17,279
Johnson & Johnson12$8,472
Veryan Medical Incorporated7$6,829
Regeneron8$4,752
Janssen Scientific Affairs, LLC3$4,569
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)3$4,026
Terumo Medical Corporation8$3,485
Cordis US CORP.7$3,254
Cardiovascular Systems Inc.5$2,649
Silk Road Medical, Inc.2$2,438
Cardinal Health 200 LLC3$2,364
Abiomed22$1,437
Angiodynamics, Inc.6$814
Novartis38$752
Heartflow, Inc.9$714
Pfizer21$416
E.r. Squibb & Sons, L.L.C.10$384
Recor Medical Inc3$353
Cardiva Medical, Inc.2$326
Contego Medical, Inc4$311
Inari Medical, Inc.3$306
Boehringer Ingelheim15$252
W. L. Gore & Associates, Inc.3$245
Inspiremd Ltd2$239
Edwards Lifesciences4$169
Amgen6$143
Acist Medical Systems, Inc.1$132
Asahi Intecc USA, Inc.2$129
CSL Behring1$125
AstraZeneca1$115
Avinger Inc.2$103
Intact Vascular, Inc.1$103
Kestra Medical Technology Services, Inc.2$67
Bridgebio Pharma, Inc.3$64
Alnylam Pharmaceuticals Inc.2$56
Siemens Medical Solutions USA, Inc.1$55
Vifor Pharma, Inc.2$48
Novo Nordisk2$47
Esperion Therapeutics, Inc.2$43
Bayer2$40
Stryker1$40
Takeda Pharmaceuticals U.S.A., Inc.2$38
Actelion Pharmaceuticals US, Inc.1$32
Daiichi Sankyo Inc.1$28
Ardelyx, Inc.1$28
Irhythm Technologies, Inc.1$25
Avanir Pharmaceuticals, Inc.1$25
Opsens Inc.1$24
Otsuka America Pharmaceutical, Inc.1$22
Amarin Pharma, Inc.1$21
Tandem Diabetes Care, Inc.1$20
Kiniksa Pharmaceuticals International, PLC1$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,685,309 in reported general payments places this provider in the 95th percentile of 382 interventional cardiology providers in New York.

See all interventional cardiology providers in New York

Medicare billing

Part B allowed, 2024
$146,725
Medicare patients
417
Services billed
1,079

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban29$28,873
XareltoRivaroxaban20$21,725
BrilintaTicagrelor12$7,760
FarxigaDapagliflozin Propanediol12$6,872
Metoprolol Succinate76$1,185
Atorvastatin Calcium65$718
Amlodipine Besylate33$426
Valsartan11$408
Ezetimibe13$299
Rosuvastatin Calcium24$264
Midodrine Hcl13$220
Losartan Potassium37$171
Gabapentin16$157
ClopidogrelClopidogrel Bisulfate35$150
Furosemide19$117

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$416$28,87329 claims
Johnson & JohnsonXarelto$8,472$21,72520 claims
AstraZenecaBrilinta, Farxiga$115$14,63124 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 382 interventional cardiology providers in New York.

Other interventional cardiology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →